iTeos Therapeutics (ITOS) Stock Price, News & Analysis

Company Overview

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $7.61 to $8.02
• 50-Day Range: $7.22 to $9.38
• 52-Week Range: $7.09 to $18.75
• Volume: 320,556 shs
• Average Volume: 441,749 shs
• Market Capitalization: $292.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.25
• Consensus Rating: Buy

iTeos Therapeutics Stock Analysis - MarketRank™

iTeos Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 222nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

iTeos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

iTeos Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for iTeos Therapeutics are expected to decrease in the coming year, from ($3.49) to ($4.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of iTeos Therapeutics is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of iTeos Therapeutics is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

iTeos Therapeutics has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.88% of the float of iTeos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

iTeos Therapeutics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in iTeos Therapeutics has recently decreased by 21.05%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iTeos Therapeutics does not currently pay a dividend.

Dividend Growth

iTeos Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.88% of the float of iTeos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

iTeos Therapeutics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in iTeos Therapeutics has recently decreased by 21.05%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.67

News Sentiment

iTeos Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for iTeos Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for ITOS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added iTeos Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, iTeos Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $38,650.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

12.50% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ITOS Stock Analysis - Frequently Asked Questions

How have ITOS shares performed this year?

iTeos Therapeutics' stock was trading at $7.68 at the beginning of the year. Since then, ITOS shares have increased by 4.2% and is now trading at $8.00.
View the best growth stocks for 2025 here.

How were iTeos Therapeutics' earnings last quarter?

iTeos Therapeutics, Inc. (NASDAQ:ITOS) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.18) by $0.13.

When did iTeos Therapeutics IPO?

iTeos Therapeutics (ITOS) raised $151 million in an IPO on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are iTeos Therapeutics' major shareholders?

Top institutional shareholders of iTeos Therapeutics include Marquette Asset Management LLC (0.04%), SG Americas Securities LLC (0.04%) and Clear Harbor Asset Management LLC (0.03%). Insiders that own company stock include Boxer Capital, Llc, Matthew Gall, Michel Detheux, David Hallal, Joanne Jenkins Lager and Yvonne Mcgrath.
View institutional ownership trends.

How do I buy shares of iTeos Therapeutics?

Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of iTeos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iTeos Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 1/20/2025
• Next Earnings (Estimated): 3/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ITOS
• CUSIP: N/A
• CIK: 1808865
• Web: www.iteostherapeutics.com
• Phone: 339-217-0161
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $22.25
• High Stock Price Target: $25.00
• Low Stock Price Target: $19.00
• Potential Upside/Downside: +178.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-112,640,000.00
• Net Margins: N/A
• Pretax Margin: -320.49%
• Return on Equity: -20.11%
• Return on Assets: -17.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.80
• Quick Ratio: 14.80

Sales & Book Value

• Annual Sales: $12.60 million
• Price / Sales: 23.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.08 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 36,530,000
• Free Float: 31,967,000
• Market Cap: $292.24 million
• Optionable: Optionable
• Beta: 1.39